Grail shares rose nearly 10% after the FDA scheduled an advisory committee review of its Galleri multi-cancer early detection blood test, despite the 142,000-participant NHS-Galleri trial missing its primary endpoint of significantly reducing Stage III-IV cancer diagnoses. The PMA application leans on data from more than 70,000 first-year NHS-Galleri participants and the 35,878-participant PATHFINDER 2 study, where Galleri detected 40% of cancers overall, 73.7% across 12 high-mortality cancers, with 99.6% specificity.

Why It Matters To Oncology

• Galleri is the first multi-cancer early detection test to reach FDA advisory committee review, making the Sept. 23 meeting a key signal for the regulatory path of MCED assays.

• The test analyzes methylation patterns in cell-free DNA to detect cancer-associated fingerprints and could expand screening beyond single-tumor programs if cleared.

• The NHS-Galleri miss raises a core clinical question: whether earlier signal detection can translate into fewer late-stage malignant neoplasm diagnoses at population scale.

The Financials

• Grail stock climbed close to 10% Friday on renewed investor optimism around a possible FDA marketing win.

• That rebound follows a sharp selloff in February, when the company lost roughly half its valuation after disclosing the NHS-Galleri primary endpoint miss.

• The market appears to be re-pricing Galleri based on the strength of the FDA review milestone and supportive performance data from PATHFINDER 2.

What They're Saying

• CEO Josh Ofman said Grail has generated extensive evidence across studies showing increased screen-detected cancers, a low false positive rate, and high accuracy in predicting tissue of origin.

• Grail also highlighted a favorable trend toward fewer late-stage diagnoses in a prespecified group of 12 cancers, including lung, pancreas, colorectal, ovarian, and liver/bile duct tumors.

• Skeptics are likely to focus on the fact that the company submitted its PMA before releasing the full NHS-Galleri results.

What's Next

• The FDA's Molecular and Clinical Genetics Panel will review Galleri's PMA on Sept. 23.

• Clinicians and drug discovery teams will be watching how regulators weigh real-world screening utility against assay performance metrics such as sensitivity, specificity, and signal-origin accuracy.

• The outcome could shape not only Galleri's commercial prospects, but also evidentiary expectations for future blood-based early cancer detection platforms.